Insights on the Human Insulin Global Market to 2026 - by Product Type, Distribution Type, Disease Type and Region - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Human Insulin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

The global human insulin market exhibited moderate growth during 2015-2020. Looking forward, the publisher expects the market to grow at a CAGR of around 5% during the forecast period (2021-2026).

Human insulin (HI) is a form of synthetic insulin that is synthesized in laboratories for pharmaceutical use. It is bio-engineered by growing insulin proteins within E-coli bacteria (Escherichia coli) cells to mimic the properties of insulin naturally present in humans. The HI drugs are available in three kinds, namely rapid-acting, long-acting and premixed. They are used as a solution or suspension and are usually injected subcutaneously and aid in promoting the uptake of glucose from the blood into internal organs, such as fat cells, skeletal muscles and liver. They also inhibit hepatic glucose production, lipolysis and proteolysis and enhance protein synthesis in the body.

The increasing prevalence of obesity and diabetes across the globe is one of the key factors driving the growth of the market. Owing to sedentary lifestyles, growing geriatric population and unhealthy dietary habits, a greater number of individuals are suffering from chronic lifestyle diseases, thereby increasing the demand for insulin therapeutics.

Furthermore, the growing requirement for biosimilar drugs, owing to their high efficiency and cost-effectiveness, is providing a boost to the market growth. Various technological advancements, such as the development of pen devices and safety pen needles, to administer HI in the body, are also creating a positive impact on the market growth. In comparison to standard needles, these safety pens ensure minimal injuries, discomfort and infections through bloodborne pathogen transmission. Other factors, including the increasing health consciousness among the masses and extensive research and development (R&D) in the field of biotechnology, are projected to drive the market further.

Companies Mentioned

• B. Braun Melsungen AG
• Becton Dickinson & Company
• Biocon
• Eli Lilly
• Company
• Julphar
• Novo Nordisk
• Pfizer
• Sanofi
• Sedico
• Wockhardt
• Ypsomed Holding

Key Questions Answered in This Report:

• How has the global human insulin market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global human insulin market?
• What are the key regional markets?
• What is the breakup of the market based on the product type?
• What is the breakup of the market based on the drug type?
• What is the breakup of the market based on the delivery devices?
• What is the breakup of the market based on the distribution channel?
• What is the breakup of the market based on the disease type?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global human insulin market and who are the key players?
• What is the degree of competition in the industry?

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Human Insulin Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Forecast

6 Market Breakup by Product Type

7 Market Breakup by Distribution Channel

8 Market Breakup by Disease Type

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Indicators

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

For more information about this report visit https://www.researchandmarkets.com/r/5ia7yf

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900